





1201


100

ŝ o-tyrosine production (%)



Control .





(%) noitoubona enizontion (%)

Figure 5



Figure 6

Blood pressure-lowering effect by drug administration




Figure 3

Urinary protein inhibiting effect by drug administration




Figure 8

Thy-1 Nephritis model




Figure 9
Thy-1 Nephritis model





Figure 10

Thy-1 Nephritis model



·Figure 11






Figure 12

Ischemia-reperfusion model




Figure 13





Figure 14








Figure 16
Stability of TM-2002 injectable lyophilized formulation




- 1. TM-2002 injectable lyophilized formulation-aqueous solution (1ml) diluted with saline (1.5 ml)
- 2. TM-2002 hydrochloride (material; prepared when used for TLC)
- 3. TM-2002 hydrochloride (material) aqueous solution


Figure 17




ORP 150 immunostaining in WKY drug free group



ORP 150 immunostaining in SHR/NDmcr—cp drug free group



ORP 150 immunostaining in SHR drug free group



ORP 150 immunostaining in SHR/NDmcr—cp TM-2002 administered group

Figure 18

